Abstract

In clinical practice, the treatment approach for hepatocellular carcinoma (HCC) with macrovascular invasion (MVI) is determined on a case-by-case basis. The common management options include systemic and local therapies, although the former is the more widely accepted approach. We present three cases of HCC with MVI successfully treated with radiotherapy. The first patient was a 62-year-old man with Child-Pugh A cirrhosis who had a 5.7-cm treatment-naïve HCC invading the bilateral branches of the portal vein. Stereotactic body radiotherapy (SBRT) was administered, with no evidence of recurrence observed at the 24-month follow-up. The second patient was an 81-year-old man with Child-Pugh A cirrhosis who had a 3.8-cm HCC invading the inferior vena cava (IVC). Transcatheter chemoembolization performed one month earlier had been ineffective, and the tumor had grown rapidly. SBRT was administered, and no evidence of recurrence was observed up to his death from pneumonia 24 months after the treatment initiation. The third patient was a 72-year-old man with Child-Pugh A cirrhosis who had a 6.7-cm treatment-naïve HCC with portal vein tumor thrombosis (PVTT) from the main trunk to the secondary branches of both lobes. PVTT was treated with hypofractionated radiotherapy, while the primary HCC and intrahepatic recurrent lesions were subsequently treated with hepatic arterial infusion chemotherapy (HAIC) and five rounds of ablation. Six months after the last ablation (48 months after initial therapy), no evidence of recurrence was observed. Our cases illustrate that radiotherapy leads to the successful treatment of HCC with MVI.

Highlights

  • For hepatocellular carcinoma (HCC) with macrovascular invasion (MVI), systemic therapy has been the most widely accepted treatment approach [1,2,3,4,5]

  • We present three cases of HCC with MVI successfully managed with radiotherapy, and discuss the role of radiotherapy as part of multidisciplinary treatment strategies

  • The resection rate of HCC with portal vein tumor thrombosis (PVTT) in the first branch was limited to 24%, due to technical demands and excessive invasiveness depending on the location and extent of the tumor thrombus

Read more

Summary

Introduction

For hepatocellular carcinoma (HCC) with macrovascular invasion (MVI), systemic therapy has been the most widely accepted treatment approach [1,2,3,4,5]. SBRT was administered with 40 Gy in five fractions to enclose the planning target volume with a 70% isodose line of the maximal dose equated to the prescribed dose (Figures 2C, 2D) Within one month, his AFP and PIVKA-II levels decreased to 14.4 ng/mL and 249 mAU/mL, respectively; the IVC lesion disappeared, and his liver function remained preserved. A 72-year-old man with alcoholic liver disease and Child-Pugh 6A cirrhosis (ALBI grade 2) presented to another hospital with a 6.7-cm treatment-naïve HCC with a massive PVTT from the main trunk to the secondary branches of both lobes (Figures 3A, 3B) His serum AFP and PIVKA-II levels were 935.0 ng/mL and 352 mAU/mL, respectively. Portal vein invasion has been thrombosed and occluded, with collateral blood vessels being formed

Discussion
Conclusions
Disclosures
Findings
European Association for the Study of the Liver
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call